S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies

Disc Medicine (IRON) Stock Price, News & Analysis

$65.00
+0.02 (+0.03%)
(As of 02/23/2024 ET)
Today's Range
$64.37
$65.93
50-Day Range
$56.98
$70.08
52-Week Range
$18.25
$70.27
Volume
233,471 shs
Average Volume
170,634 shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.56

Disc Medicine MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.7% Downside
$64.56 Price Target
Short Interest
Bearish
5.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Disc Medicine in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$21.94 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.24) to ($3.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.15 out of 5 stars

Medical Sector

915th out of 939 stocks

Pharmaceutical Preparations Industry

422nd out of 433 stocks


IRON stock logo

About Disc Medicine Stock (NASDAQ:IRON)

Disc Medicine, Inc., together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

IRON Stock Price History

IRON Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
FDA Grants Orphan Drug Designation to 9MW3011
Brokerages Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $64.56
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE
A shocking leak has revealed tech giant Microsoft plans to add crypto support to future products. If the plans in these leaked documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, and MORE. The coupling of gaming and cryptocurrency could transform digital finance as we know it. We've gathered 27 experts to share their top picks and predictions for the 2024 crypto bull run.
IRON Mar 2024 70.000 call
IRON Mar 2024 80.000 put
Disc Medicine Receives FDA ODD For DISC-3405
Best Zero-Gravity Chairs for 2024
Disc Medicine: What's Behind The Huge Rally
Disc Medicine Inc Ordinary Shares IRON
See More Headlines
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
2/24/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IRON
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$64.56
High Stock Price Target
$85.00
Low Stock Price Target
$36.00
Potential Upside/Downside
-0.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-46,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$10.15 per share

Miscellaneous

Free Float
23,003,000
Market Cap
$1.57 billion
Optionable
Not Optionable
Beta
0.18
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Donald William Nicholson Ph.D. (Age 65)
    Independent Executive Chairman
    Comp: $150k
  • Dr. John D. Quisel Esq. (Age 53)
    J.D., Ph.D., CEO, President, Secretary & Director
    Comp: $750.12k
  • Mr. Jonathan Yu (Age 42)
    Chief Opearating Officer
    Comp: $539.32k
  • Dr. William Jacob Savage M.D. (Age 49)
    Ph.D., Chief Medical Officer
    Comp: $571.95k
  • Dr. Brian MacDonald ChB (Age 64)
    MB, Ph.D., Founder & Chair of Scientific Advisory Board
    Comp: $88.54k
  • Ms. Jean M. Franchi (Age 58)
    Chief Financial Officer
  • Dr. Rahul Khara J.D. (Age 42)
    Pharm.D., General Counsel, Compliance Officer & Secretary
  • Mr. Srikanth Venkatraman Ph.D.
    Senior VP & Head of Chemistry
  • Ms. Hua Yang Ph.D.
    Senior Vice President of Nonclinical Development














IRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Disc Medicine stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last twelve months. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRON shares.
View IRON analyst ratings
or view top-rated stocks.

What is Disc Medicine's stock price target for 2024?

10 brokers have issued 1-year price objectives for Disc Medicine's shares. Their IRON share price targets range from $36.00 to $85.00. On average, they expect the company's stock price to reach $64.56 in the next year. This suggests that the stock has a possible downside of 0.7%.
View analysts price targets for IRON
or view top-rated stocks among Wall Street analysts.

How have IRON shares performed in 2024?

Disc Medicine's stock was trading at $57.76 on January 1st, 2024. Since then, IRON shares have increased by 12.5% and is now trading at $65.00.
View the best growth stocks for 2024 here
.

Are investors shorting Disc Medicine?

Disc Medicine saw a increase in short interest in January. As of January 31st, there was short interest totaling 1,320,000 shares, an increase of 7.3% from the January 15th total of 1,230,000 shares. Based on an average trading volume of 251,800 shares, the short-interest ratio is presently 5.2 days.
View Disc Medicine's Short Interest
.

When is Disc Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our IRON earnings forecast
.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.12.

What ETFs hold Disc Medicine's stock?

ETFs with the largest weight of Disc Medicine (NASDAQ:IRON) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

Who are Disc Medicine's major shareholders?

Disc Medicine's stock is owned by many different retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (10.58%), Frazier Life Sciences Management L.P. (3.25%), Vanguard Group Inc. (3.17%), Price T Rowe Associates Inc. MD (2.45%), Price T Rowe Associates Inc. MD (2.45%) and Franklin Resources Inc. (0.92%). Insiders that own company stock include Brian Richard Macdonald, Holdings A/S Novo, Joanne Bryce, Kevin Bitterman, Mona Ashiya, Orbimed Advisors Llc, Rahul Khara, Venture Fund X LP Atlas and William Jacob Savage.
View institutional ownership trends
.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRON) was last updated on 2/24/2024 by MarketBeat.com Staff